We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 18.00 | 23.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
27/11/2018 14:49 | This was for Latin American rights only. If they sell ROW minus US/N America it should fund any gap to complete? "Under the terms of the licence and commercialisation agreement, Summit will receive an upfront payment of $2.5 million, and is entitled to receive a further $3.75 million in development milestones upon the achievement of staged patient enrolment targets in the planned Phase 3 clinical trials of ridinilazole. Summit is eligible to receive up to an additional $21.4 million through other development milestones, commercial milestones, and one-time sales milestones based on cumulative net sales up to $100 million in the Licensed Territory. Further, the agreement provides for product supply transfer payments expected to provide a return equivalent to a high single digit to low double-digit percentage of net sales. For each incremental $100 million in cumulative net sales achieved, Summit is entitled to a further milestone payment which, when combined with the aforementioned product supply transfer payments, is expected to provide a return equivalent to a mid- to high-teens percentage of net sales. " | waterloo01 | |
27/11/2018 14:38 | Just a moment. Wellcome funded the phase 2 and Barda have already committed $42m out of possible $62m, they have sold rights in South America, so hardly no interest, but yes, antibiotics remain the unloved drug discoveries. The phase 3 will start early next year. It's funded to start. | waterloo01 | |
27/11/2018 14:28 | I wonder what is, or what was the purpose of Moux Ltd, other than to provide a vehicle that presumably Summit as the the ultimate parent company may have made payments to for certain services. Anyway its dormant and just Glyn as a sole director. Why not juts shut it down? C-Diff is probably going the same way- Big Pharma just not interested in new antibiotics- 1) limited lifespan-mutation 2) govt interference 3) tiny margins all make it a very uncommercial proposition which is in my view why Summit has never managed to find a partner to take this drug to market, which is extremely costly in itself and hence no suitors despite Summ's lowly market cap. | lagosboy | |
27/11/2018 11:23 | From my share watch today: Name Muox Limited 136A Eastern Avenue, Milton Park, Abingdon, Oxfordshire OX14 4SB Status DORMANT Relation – Latest Activity Accounts Submitted 3 Months 30 Jul 2018 Edit: That says it all as far as DMD is concerned. | chrisatrdg | |
23/11/2018 16:30 | Very tight spread and a number of trades this afternoon? | waterloo01 | |
22/11/2018 11:38 | My reply to EP: Hi EP - Good to hear from you & yes my portfolio is looking dire with the exception of INFA. I do on occasion speak to Summit & have at no time detected a problem that we had not been told about.The science is therefore still sound unless told otherwise.I think that there is no appetite in the US for the current range of sciences that Summit has as I believe that it was DMD they were interested in & the continual drop on the NASDAQ has worsened the situation.In addition I guess there is a large overhang of shares anticipated to come onto the market. We will have a better idea week after next week when I expect we will receive the results for the 9 months ending 31st October 2018 at which point we will have a better idea as to how far Summits cash runway extends too. On a more positive note the current share price will enable me to Buy more shares when my remaining portfolio springs to life & intend increasing my holding of 50,000 shares by a further 25,000 or 50,000 but not likely to 1st Qtr next year. My current average is 96p & I still believe that this will be matched sometime next year & have never thought it would be this year & is why those with funds currently have a bargain at todays share price hence my comment is Strong Buy. | chrisatrdg | |
22/11/2018 11:37 | Per English Parisien on the other board this morning: "No idea. Just looking at my portfolio ... it's a sea of profound red. The AIM market of old is no more Fingers crossed that one day (most likely in a galaxy far far away ...) I will be able to claw back a decent chunk, if not all, of my original investments I had heavily counted on that being this summer, here, with you fellow investors ... but alas that was not to be GLA - EP' | chrisatrdg | |
22/11/2018 08:43 | Quite ironic the days NASDAQ share price has been falling and we haven't moved in the one day it goes up we go down in the UK | football | |
21/11/2018 21:51 | UK pledges £5m to fight 'super gonorrhea' 21 NOVEMBER 2018 • 5:48PM The UK government has pledged £5 million for the development of new tools for the diagnosis of “super gonorrhea” as part of a renewed push to combat the rising tide of superbugs around the world. Professor Dame Sally Davies, chief medical officer for England, has announced an extra £11.5 million to tackle antimicrobial resistance (AMR), nearly half of which will go on the development of a rapid, point-of-care test for drug-resistant gonorrhea. The government is due to launch a new AMR strategy in the new year, with the aim by 2040 of controlling what Dame Sally says "threatens the future of modern medicine". “Super gonorrhea" is spiralling out of control around the world and earlier this year the world’s “worst ever” case was diagnosed in a man from the East Midlands who picked up the bug while on holiday in South East Asia. Two standard antibiotics failed to cure his infection and he had to have a three-day intravenous infusion of the antibiotic ertapenem. The £5m will go to the non-profit partnership the Foundation for Innovative New Diagnostics (FIND) for the development of a test that will be ready for use by 2025. read more | football | |
19/11/2018 21:57 | New low in NYC today 1.27 equal to 19.7p . What a steal, I wonder if someone delibearately pushes the price down to be able to come with a fantastic 50% premium in a bid, and get the co for less than cash :-) | multiplural | |
19/11/2018 19:24 | Will be going up tomorrow I think | kirk 6 | |
18/11/2018 13:57 | Technical, no other real reason. Most stocks that aren't dead and have fallen this much do a 100-200% bounce. Made a fortunes from it in the past and I reckon before Christmas this will be over 40p.Imm came to glory last week and I will make a profit out of that.Expect a 100-200% rise very shortly here. | kirk 6 | |
18/11/2018 13:50 | Why? Other than that is what you need it to do to be in profit..... | nobbygnome | |
18/11/2018 13:44 | Expecting SUMM will rise from the ashes very soon. 100-200% rise shortly on the cards here | kirk 6 | |
15/11/2018 15:21 | Summit Therapeutics @Summitplc e According to @CDCgov up to 50% of #antibiotics prescribed in US hospitals are unnecessary or inappropriate. This contributes to serious problems like #Cdiff and #AntibioticResistanc 3:17 PM - 15 Nov 2018 | football | |
15/11/2018 15:21 | Summit Therapeutics @Summitplc e According to @CDCgov up to 50% of #antibiotics prescribed in US hospitals are unnecessary or inappropriate. This contributes to serious problems like #Cdiff and #AntibioticResistanc 3:17 PM - 15 Nov 2018 | football | |
13/11/2018 21:16 | I am heavily in this around mid 30s though and have only added 50k in the 20s took out a big stake in low to mid 30s thinking that must be the Bottom. | kirk 6 | |
13/11/2018 19:10 | Hi All -I would have added today but no funds however if my INFA shares move I will be adding at least 25,000 shares maybe 50,000 in order to average down.I still believe in the company & I believe others are also thinking now is the time to Buy.I am envious Kirk 6 of your ability to Buy at the levels you are I am sure it will pay off. | chrisatrdg | |
13/11/2018 16:46 | Added 50 will add another 50 later in week | kirk 6 | |
13/11/2018 16:24 | I added some today. !! | waterloo01 | |
13/11/2018 16:03 | Looking good on the NASDAQ this afternoon 5,000 at $1.54 (9.22%) hopefully this will Hold & a small increase on AIM 1.5P (6.98%)has the worm finally turned. | chrisatrdg | |
12/11/2018 11:04 | Could well be up for sale trading significantly below cash.Good news | kirk 6 | |
12/11/2018 10:55 | Perhaps they are looking to merge some biotechs together....I am tempted to say when you put 2 piles of sh*t together all you get is a big pile of sh*t but I will desist! | nobbygnome |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions